Interview with Elisabeth Beck, Managing Director, IMS Health Germany
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
Address: Darmstädter Landstraße 108
60598 Frankfurt/Main,Germany
Tel: +49 (0)69/6604-0
Web: http://www.imshealth.com/portal/site/ims?CURRENT_LOCALE=de_de
IMS was founded in 1954 in New York. The German subsidiary was registered in 1959. Today there are more than 100 branches with more than 7,000 employees. IMS applies leading-edge technologies to transform billions of pharmaceutical transactions collected from thousands of sources into strategic insights.
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
See our Cookie Privacy Policy Here
